Combining Radiation Therapy with Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Expert Commentary
Immune checkpoint blockade (ICB) demonstrated modest clinical activity in patients with metastatic castration-resistant prostate cancer (CRPC). However, it is unclear if radiation therapy synergizes with ICB to enhance the antitumor immune response.